FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095873383> ?p ?o ?g. }

• W2095873383 endingPage "251" @default.
• W2095873383 startingPage "242" @default.
• W2095873383 abstract "Advanced prostate cancer is treated by androgen ablation and/or androgen receptor (AR) antagonists. In order to investigate the mechanisms relevant to the development of therapy-resistant tumours, we established a new tumour model which closely resembles the situation in patients who receive androgen ablation therapy. Androgen-sensitive LNCaP cells were kept in androgen-depleted medium for 87 passages. The new LNCaP cell subline established in this manner, LNCaP-abl, displayed a hypersensitive biphasic proliferative response to androgen until passage 75. Maximal proliferation of LNCaP-abl cells was achieved at 0.001 nM of the synthetic androgen methyltrienolone (R1881), whereas 0.01 nM of this compound induced the same effect in parental cells. At later passages (> 75), androgen exerted an inhibitory effect on growth of LNCaP-abl cells. The non-steroidal anti-androgen bicalutamide stimulated proliferation of LNCaP-abl cells. AR protein expression in LNCaP-abl cells increased approximately fourfold. The basal AR transcriptional activity was 30-fold higher in LNCaP-abl than in LNCaP cells. R1881 stimulated reporter gene activity in LNCaP-abl cells even at 0.01 nM, whereas 0.1 nM of R1881 was needed for induction of the same level of reporter gene activity in LNCaP cells. Bicalutamide that acts as a pure antagonist in parental LNCaP cells showed agonistic effects on AR transactivation activity in LNCaP-abl cells and was not able to block the effects of androgen in these cells. The non-steroidal AR blocker hydroxyflutamide exerted stimulatory effects on AR activity in both LNCaP and LNCaP-abl cells; however, the induction of reporter gene activity by hydroxyflutamide was 2.4- to 4-fold higher in the LNCaP-abl subline. The changes in AR activity were associated neither with a new alteration in AR cDNA sequence nor with amplification of the AR gene. Growth of LNCaP-abl xenografts in nude mice was stimulated by bicalutamide and repressed by testosterone. In conclusion, our results show for the first time that the nonsteroidal anti-androgen bicalutamide acquires agonistic properties during long-term androgen ablation. These findings may have repercussions on the natural course of prostate cancer with androgen deprivation and on strategies of therapeutic intervention." @default.
• W2095873383 created "2016-06-24" @default.
• W2095873383 creator A5002682008 @default.
• W2095873383 creator A5006782095 @default.
• W2095873383 creator A5007312106 @default.
• W2095873383 creator A5007518185 @default.
• W2095873383 creator A5008951210 @default.
• W2095873383 creator A5029009712 @default.
• W2095873383 creator A5044922503 @default.
• W2095873383 creator A5045579256 @default.
• W2095873383 creator A5056429133 @default.
• W2095873383 creator A5067267656 @default.
• W2095873383 creator A5067705347 @default.
• W2095873383 date "1999-08-27" @default.
• W2095873383 modified "2023-10-16" @default.
• W2095873383 title "Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system" @default.
• W2095873383 cites W1419228847 @default.
• W2095873383 cites W1493268813 @default.
• W2095873383 cites W1595712080 @default.
• W2095873383 cites W1896753574 @default.
• W2095873383 cites W1943507320 @default.
• W2095873383 cites W1948931726 @default.
• W2095873383 cites W1969293666 @default.
• W2095873383 cites W1970841622 @default.
• W2095873383 cites W1988679331 @default.
• W2095873383 cites W1995712305 @default.
• W2095873383 cites W1998718563 @default.
• W2095873383 cites W2008498145 @default.
• W2095873383 cites W2009269691 @default.
• W2095873383 cites W2009402948 @default.
• W2095873383 cites W2013981968 @default.
• W2095873383 cites W2014038908 @default.
• W2095873383 cites W2020220783 @default.
• W2095873383 cites W2022635468 @default.
• W2095873383 cites W2029675948 @default.
• W2095873383 cites W2033304819 @default.
• W2095873383 cites W2033344337 @default.
• W2095873383 cites W2033507378 @default.
• W2095873383 cites W2037365073 @default.
• W2095873383 cites W2040316588 @default.
• W2095873383 cites W2041688913 @default.
• W2095873383 cites W2051967652 @default.
• W2095873383 cites W2057477877 @default.
• W2095873383 cites W2063921595 @default.
• W2095873383 cites W2066570340 @default.
• W2095873383 cites W2069747703 @default.
• W2095873383 cites W2070301852 @default.
• W2095873383 cites W2080989291 @default.
• W2095873383 cites W2107204091 @default.
• W2095873383 cites W2112248146 @default.
• W2095873383 cites W2129750923 @default.
• W2095873383 cites W2137330819 @default.
• W2095873383 cites W2142365640 @default.
• W2095873383 cites W2147405625 @default.
• W2095873383 cites W2149865992 @default.
• W2095873383 cites W2155445409 @default.
• W2095873383 cites W2159448513 @default.
• W2095873383 cites W2164416692 @default.
• W2095873383 cites W2340799873 @default.
• W2095873383 cites W262100597 @default.
• W2095873383 cites W2766162865 @default.
• W2095873383 doi "https://doi.org/10.1038/sj.bjc.6690684" @default.
• W2095873383 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2362859" @default.
• W2095873383 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10496349" @default.
• W2095873383 hasPublicationYear "1999" @default.
• W2095873383 type Work @default.
• W2095873383 sameAs 2095873383 @default.
• W2095873383 citedByCount "394" @default.
• W2095873383 countsByYear W20958733832012 @default.
• W2095873383 countsByYear W20958733832013 @default.
• W2095873383 countsByYear W20958733832014 @default.
• W2095873383 countsByYear W20958733832015 @default.
• W2095873383 countsByYear W20958733832016 @default.
• W2095873383 countsByYear W20958733832017 @default.
• W2095873383 countsByYear W20958733832018 @default.
• W2095873383 countsByYear W20958733832019 @default.
• W2095873383 countsByYear W20958733832020 @default.
• W2095873383 countsByYear W20958733832021 @default.
• W2095873383 countsByYear W20958733832022 @default.
• W2095873383 countsByYear W20958733832023 @default.
• W2095873383 crossrefType "journal-article" @default.
• W2095873383 hasAuthorship W2095873383A5002682008 @default.
• W2095873383 hasAuthorship W2095873383A5006782095 @default.
• W2095873383 hasAuthorship W2095873383A5007312106 @default.
• W2095873383 hasAuthorship W2095873383A5007518185 @default.
• W2095873383 hasAuthorship W2095873383A5008951210 @default.
• W2095873383 hasAuthorship W2095873383A5029009712 @default.
• W2095873383 hasAuthorship W2095873383A5044922503 @default.
• W2095873383 hasAuthorship W2095873383A5045579256 @default.
• W2095873383 hasAuthorship W2095873383A5056429133 @default.
• W2095873383 hasAuthorship W2095873383A5067267656 @default.
• W2095873383 hasAuthorship W2095873383A5067705347 @default.
• W2095873383 hasBestOaLocation W20958733831 @default.
• W2095873383 hasConcept C121608353 @default.
• W2095873383 hasConcept C126322002 @default.
• W2095873383 hasConcept C134018914 @default.
• W2095873383 hasConcept C2777911890 @default.
• W2095873383 hasConcept C2779322244 @default.

• next